Comparative Effectiveness and Safety of Emerging Myasthenia Gravis Therapies: Insights From a Bayesian Network Meta-Analysis
A Bayesian network meta-analysis comparing FcRn inhibitors, C5 complement inhibitors, and CD19+ B-cell depletion therapies reveals comparable efficacy but varied safety profiles in generalized myasthenia gravis treatment, highlighting the need for prospective head-to-head trials.